

NEWS RELEASE

Solna, May 18th, 2018

Eurocine Vaccines has completed dosing of its quadrivalent influenza vaccine candidate, Immunose™ FLU, in the second clinical study

This week, dosing was completed according to plan in the second clinical study with Immunose™ FLU, developed with the aim to become a modern and effective nasal influenza vaccine.

- In the perspective of this year's severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna-Karin Maltais, Chief Scientific Officer.

-The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine in this segment. This, without losing sight of our vision, to offer the first nasal influenza vaccine for children younger than 2 years, adds Hans Arwidsson, CEO of Eurocine Vaccines.

The strategy behind this present study, and its design, was presented in a previous news release dated February 7th, 2018 and can be read at;

<https://www.eurocine-vaccines.com/en/eurocine-vaccines-takes-advantage-of-yet-another-influenza-season-launching-its-second-clinical-study-on-immunose-flu/>

The progress of the study can also be followed at; <https://clinicaltrials.gov>
Results are expected second half of 2018.

For more information, please contact:

Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine - vaccines.com
+46 70 634 0171

About Eurocine Vaccines

Eurocine Vaccines is using its clinically validated technology Endocine™ to develop patent protected nasal vaccines. Endocine™, based on endogenous components, brings advantages such as creation of both mucosal and systemic immunity, as well as needle-free and convenient nasal vaccination.

The company's first product candidate, the nasal quadrivalent influenza vaccine Immunose™ FLU, is currently in clinical phase I/II development, targeted to become the first approved nasal influenza vaccine for children under the age of 2 years. Within the market for influenza vaccines, children is the fastest growing segment. This is due to the recommendation by the WHO to vaccinate children against influenza.

A clinical study conducted with Immunose™ FLU in young adults in the season 2016/2017 showed good safety and immune responses in both nasal mucosa and in serum, which constitutes a good foundation for further development. The next clinical study takes place during the present influenza season, 2017/2018, and includes elderly subjects to generate necessary safety data. Concurrently, the elderly population will be evaluated as an additional business opportunity.

Eurocine Vaccines, EUCI, is traded at Aktietorget, XSAT.